Cogent Biosciences vs GRAIL

Cogent Biosciences (COGT), health care, and GRAIL (GRAL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Cogent Biosciences and GRAIL are valued at about the same: $4.8B and $4.8B. Over the past year Cogent Biosciences's share price has moved -17.8% and GRAIL's +29.6%.

Key facts

Cogent Biosciences market value
$4.8B
GRAIL market value
$4.8B
GRAIL revenue
$147.2MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Cogent Biosciences vs GRAIL: every measure side by side
Measure Cogent Biosciences GRAIL
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$4.8Bhigher$4.8Blower
Revenue—$147.2M
Earnings-$328.9Mhigher-$408.4Mlower
Employees258lower910higher
Total assets$937.6Mlower$2.9Bhigher
Valuation
P/E——
P/S—32.3
P/B10.7higher1.9lower
Dividend yield0.00%0.00%
Profitability
Operating margin—-382%
Balance sheet
Net assets$636.4Mlower$2.6Bhigher
Total liabilities$301.2Mlower$344.2Mhigher
Total debt$222.9M—
Cash on hand$312Mhigher$249.7Mlower
Price change
Today+1.49%higher+0.27%lower
1 year-17.8%lower+29.6%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Cogent Biosciences only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Cogent Biosciences / GRAIL). Who owns COGT · Who owns GRAL

Further comparisons

Learn

Questions and answers

Which is bigger, Cogent Biosciences or GRAIL?

By market value, Cogent Biosciences is the larger: $4.8B against $4.8B for GRAIL.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Cogent Biosciences and GRAIL?

In their latest 13F filings, Andrew Spokes holds both.

Cite this page

Funkfolio, “Cogent Biosciences vs GRAIL”, data as of 18 November 2026. https://funkfolio.com/compare/cogt-vs-gral

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.